| 1 |
33297669 |
10.3324/haematol.2020.267294 |
2022 |
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. |
KRAS |
| 2 |
33509945 |
10.1136/jclinpath-2020-207339 |
2022 |
Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice. |
KRAS |
| 3 |
33722842 |
10.1136/jclinpath-2020-207205 |
2022 |
Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung. |
KRAS |
| 4 |
33730843 |
10.3324/haematol.2020.269431 |
2022 |
Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. |
KRAS |
| 5 |
34015890 |
10.4143/crt.2021.218 |
2022 |
Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations. |
KRAS |
| 6 |
34193976 |
10.1038/s41375-021-01326-x |
2022 |
Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. |
KRAS |
| 7 |
34472720 |
10.1002/cnr2.1545 |
2022 |
Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. |
KRAS |
| 8 |
34799485 |
10.1097/PAS.0000000000001834 |
2022 |
Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation. |
KRAS |
| 9 |
34998786 |
10.1016/j.clml.2021.12.008 |
2022 |
The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia. |
KRAS |
| 10 |
35004079 |
10.7759/cureus.20914 |
2022 |
The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia. |
KRAS |
| 11 |
35012520 |
10.1186/s12890-021-01803-0 |
2022 |
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. |
KRAS |
| 12 |
35039569 |
10.1038/s41598-021-04736-0 |
2022 |
Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma. |
KRAS |
| 13 |
35065344 |
10.1016/j.lungcan.2022.01.005 |
2022 |
A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer. |
KRAS |
| 14 |
35091678 |
10.1038/s41388-021-02162-0 |
2022 |
An mRNA expression-based signature for oncogene-induced replication-stress. |
KRAS |
| 15 |
35092381 |
10.31557/APJCP.2022.23.1.131 |
2022 |
Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. |
KRAS |
| 16 |
35123209 |
10.1016/j.esmoop.2021.100337 |
2022 |
Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients. |
KRAS |
| 17 |
35133871 |
10.1200/JCO.21.01648 |
2022 |
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. |
KRAS |
| 18 |
35138919 |
10.1200/PO.21.00424 |
2022 |
Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. |
KRAS |
| 19 |
35172382 |
10.1002/JLB.5A0721-361R |
2022 |
Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic. |
KRAS |
| 20 |
35198656 |
10.1016/j.ejro.2022.100400 |
2022 |
Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis. |
KRAS |
| 21 |
35231988 |
10.3760/cma.j.issn.0253-2727.2022.01.005 |
2022 |
[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology]. |
KRAS |
| 22 |
35240014 |
10.4143/crt.2022.017 |
2022 |
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. |
KRAS |
| 23 |
35280362 |
10.21037/atm-22-412 |
2022 |
Genomic landscape and prognosis of patients with <i>TP53</i>-mutated non-small cell lung cancer. |
KRAS |
| 24 |
35351263 |
10.7499/j.issn.1008-8830.2109141 |
2022 |
Detection of <i>RAS</i> gene mutation and its clinical significance in children with acute lymphoblastic leukemia. |
KRAS |
| 25 |
35353542 |
10.1126/scitranslmed.abc7480 |
2022 |
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. |
KRAS |
| 26 |
35359041 |
10.3760/cma.j.cn112151-20211028-00781 |
2022 |
[Characteristics of fusion gene expression in acute lymphoblastic leukemia]. |
KRAS |
| 27 |
35363510 |
10.1200/JCO.21.02840 |
2022 |
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. |
KRAS |
| 28 |
35484682 |
10.3324/haematol.2021.280557 |
2022 |
Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. |
KRAS |
| 29 |
35510120 |
10.25259/Cytojournal_18_2021 |
2022 |
Adequacy of pleural fluid cytology for comprehensive molecular analysis of lung adenocarcinoma: Experience of a large health-care system. |
KRAS |
| 30 |
35517800 |
10.3389/fphar.2022.875330 |
2022 |
Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. |
KRAS |
| 31 |
35582532 |
10.20517/cdr.2021.85 |
2022 |
Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study. |
KRAS |
| 32 |
35646685 |
10.3389/fonc.2022.713476 |
2022 |
A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines. |
KRAS |
| 33 |
35669427 |
10.3389/fonc.2022.873111 |
2022 |
Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma. |
KRAS |
| 34 |
35723561 |
10.1002/cncy.22609 |
2022 |
Machine learning-based gene alteration prediction model for primary lung cancer using cytologic images. |
KRAS |
| 35 |
35727053 |
10.1002/cncr.34348 |
2022 |
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. |
KRAS |
| 36 |
35739536 |
10.1186/s12920-022-01291-z |
2022 |
A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib. |
KRAS |
| 37 |
35748237 |
10.2217/pme-2021-0059 |
2022 |
Targeting molecular alterations in non-small-cell lung cancer: what's next? |
KRAS |
| 38 |
35806042 |
10.3390/ijms23137037 |
2022 |
State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. |
KRAS |
| 39 |
35870258 |
10.1016/j.lungcan.2022.07.011 |
2022 |
Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer. |
KRAS |
| 40 |
35892000 |
10.5114/kitp.2022.117498 |
2022 |
Computed tomography-guided lung biopsy for molecular tests: a meta-analysis. |
KRAS |
| 41 |
35895495 |
10.1002/1878-0261.13295 |
2022 |
Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model. |
KRAS |
| 42 |
35899444 |
10.3779/j.issn.1009-3419.2022.102.19 |
2022 |
[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy]. |
KRAS |
| 43 |
35920299 |
10.1096/fj.202200061RR |
2022 |
Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. |
KRAS |
| 44 |
35980949 |
10.1371/journal.pone.0273207 |
2022 |
Various impacts of driver mutations on the PD-L1 expression of NSCLC. |
KRAS |
| 45 |
35981360 |
10.19746/j.cnki.issn.1009-2137.2022.04.011 |
2022 |
[The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines]. |
KRAS |
| 46 |
36017149 |
10.1155/2022/7904293 |
2022 |
Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia. |
KRAS |
| 47 |
36077521 |
10.3390/ijms231710117 |
2022 |
Small RNA-Seq Reveals Similar miRNA Transcriptome in Children and Young Adults with T-ALL and Indicates miR-143-3p as Novel Candidate Tumor Suppressor in This Leukemia. |
KRAS |
| 48 |
32414848 |
10.3324/haematol.2019.241729 |
2021 |
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. |
KRAS |
| 49 |
32693409 |
10.1182/blood.2020006164 |
2021 |
Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. |
KRAS |
| 50 |
32852896 |
10.1002/cjp2.177 |
2021 |
Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation. |
KRAS |
| 51 |
32918044 |
10.1038/s41375-020-01036-w |
2021 |
An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance. |
KRAS |
| 52 |
32929178 |
10.1038/s41379-020-00673-x |
2021 |
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. |
KRAS |
| 53 |
33147938 |
10.3324/haematol.2020.259226 |
2021 |
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations |
KRAS |
| 54 |
33277443 |
10.1158/1535-7163.MCT-19-0987 |
2021 |
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. |
KRAS |
| 55 |
33393503 |
10.1172/JCI133090 |
2021 |
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors. |
KRAS |
| 56 |
33397922 |
10.1038/s41467-020-20255-4 |
2021 |
A RAC-GEF network critical for early intestinal tumourigenesis. |
KRAS |
| 57 |
33469311 |
10.2147/OTT.S276912 |
2021 |
Case Report: Myeloid Sarcoma Development During Treatment for B Cell Lymphoblastic Lymphoma in a Boy with KRAS/NRAS Gene Mutations. |
KRAS |
| 58 |
33475256 |
10.1111/1759-7714.13829 |
2021 |
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report. |
KRAS |
| 59 |
33494549 |
10.3390/ph14020080 |
2021 |
Therapeutic Sequencing in ALK<sup>+</sup> NSCLC. |
KRAS |
| 60 |
33506327 |
10.1007/s00428-021-03032-6 |
2021 |
Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases. |
KRAS |
| 61 |
33512434 |
10.1182/blood.2020009082 |
2021 |
Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors. |
KRAS |
| 62 |
33532178 |
10.1016/j.apsb.2020.07.010 |
2021 |
Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies. |
KRAS |
| 63 |
33552685 |
10.1080/2162402X.2020.1865653 |
2021 |
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. |
KRAS |
| 64 |
33569430 |
10.21037/atm-20-7574 |
2021 |
Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. |
KRAS |
| 65 |
33572152 |
10.3390/cancers13040694 |
2021 |
Dual Targeting Oncoproteins MYC and HIF1α Regresses Tumor Growth of Lung Cancer and Lymphoma. |
KRAS |
| 66 |
33655698 |
10.1002/cam4.3649 |
2021 |
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. |
KRAS |
| 67 |
33656807 |
10.1002/cam4.3769 |
2021 |
Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. |
KRAS |
| 68 |
33671873 |
10.3390/cancers13040804 |
2021 |
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. |
KRAS |
| 69 |
33685866 |
10.1158/1078-0432.CCR-21-0032 |
2021 |
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. |
KRAS |
| 70 |
33749383 |
10.1177/10935266211001308 |
2021 |
Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); <i>KMT2A/EPS15</i>, Following Blinatumomab Therapy. |
KRAS |
| 71 |
33750258 |
10.1080/0284186X.2021.1900908 |
2021 |
Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype. |
KRAS |
| 72 |
33807876 |
10.3390/ijms22052625 |
2021 |
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. |
KRAS |
| 73 |
33847923 |
10.1007/s12094-021-02579-9 |
2021 |
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). |
KRAS |
| 74 |
33889526 |
10.21037/tlcr-20-1290 |
2021 |
High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations. |
KRAS |
| 75 |
33889527 |
10.21037/tlcr-21-160 |
2021 |
Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. |
KRAS |
| 76 |
33898318 |
10.3389/fonc.2021.647598 |
2021 |
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients. |
KRAS |
| 77 |
33902046 |
10.1159/000514648 |
2021 |
Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. |
KRAS |
| 78 |
34024223 |
10.1080/10428194.2021.1919660 |
2021 |
Co-occurrence of <i>KIT</i> and <i>NRAS</i> mutations defines an adverse prognostic core-binding factor acute myeloid leukemia. |
KRAS |
| 79 |
34035082 |
10.1158/0008-5472.CAN-20-2823 |
2021 |
Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma. |
KRAS |
| 80 |
34074758 |
10.1073/pnas.2019740118 |
2021 |
Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. |
KRAS |
| 81 |
34094825 |
10.1016/j.apsb.2020.10.019 |
2021 |
New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors. |
KRAS |
| 82 |
34164626 |
10.1158/2643-3230.BCD-20-0203 |
2021 |
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients. |
KRAS |
| 83 |
34230493 |
10.1038/s41467-021-24442-9 |
2021 |
Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia. |
KRAS |
| 84 |
34277785 |
10.21037/atm-21-2256 |
2021 |
Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces. |
KRAS |
| 85 |
34298439 |
10.1016/j.prp.2021.153551 |
2021 |
Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis. |
KRAS |
| 86 |
34299796 |
10.3390/ijerph18147345 |
2021 |
The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border. |
KRAS |
| 87 |
34302028 |
10.1038/s41598-021-94566-x |
2021 |
Development of thymic tumor in [LSL:Kras<sup>G12D</sup>; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis. |
KRAS |
| 88 |
34321240 |
10.1158/0008-5472.CAN-21-1027 |
2021 |
Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL. |
KRAS |
| 89 |
34337566 |
10.1016/j.xcrm.2021.100350 |
2021 |
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. |
KRAS |
| 90 |
34343999 |
10.1159/000514821 |
2021 |
Multigene Combined Detection by RT-qPCR Using Cytological Specimens. |
KRAS |
| 91 |
34353680 |
10.1016/j.lungcan.2021.06.002 |
2021 |
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. |
KRAS |
| 92 |
34412631 |
10.1186/s12935-021-02143-z |
2021 |
Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling. |
KRAS |
| 93 |
34428672 |
10.1016/j.bios.2021.113568 |
2021 |
Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients. |
KRAS |
| 94 |
34434995 |
10.12998/wjcc.v9.i22.6287 |
2021 |
Diagnostic and prognostic value of secreted protein acidic and rich in cysteine in the diffuse large B-cell lymphoma. |
KRAS |
| 95 |
34447369 |
10.3389/fimmu.2021.671755 |
2021 |
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management. |
KRAS |
| 96 |
34479175 |
10.1016/j.lungcan.2021.08.012 |
2021 |
Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma. |
KRAS |
| 97 |
34548910 |
10.18632/oncotarget.28062 |
2021 |
Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibition. |
KRAS |
| 98 |
34570179 |
10.1182/bloodadvances.2021004668 |
2021 |
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. |
KRAS |
| 99 |
34584457 |
10.2147/CMAR.S317319 |
2021 |
Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma. |
KRAS |
| 100 |
34600407 |
10.1016/j.lungcan.2021.09.011 |
2021 |
Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. |
KRAS |
Datasets
Models
